Please login to the form below

Not currently logged in
Email:
Password:

Acorda Therapeutics

This page shows the latest Acorda Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Biogen pays $590m for Pfizer cognition drug

Biogen pays $590m for Pfizer cognition drug

The biotech company has also been linked to a possible takeover offer for Acorda Therapeutics and its Parkinson’s diseases candidates Inbrija (inhaled levodopa) and SYN-201.

Latest news

  • Acorda acquires Biotie to expand in Parkinson's disease Acorda acquires Biotie to expand in Parkinson's disease

    Acorda acquires Biotie to expand in Parkinson's disease. Strikes $363m deal for Finnish firm. ... Acorda Therapeutics has agreed to buy Finland's Biotie Therapies in a $363m deal that swells its pipeline of Parkinson's disease (PD) drug candidates.

  • Pharma deals for February 2012 Pharma deals for February 2012

    For example, the acquisition of the privately-owned Neuronex, with its diazepam nasal spray, by Acorda Therapeutics reads like a licensing deal: $2m upfront; some R&D payments; $18m development and ... 300. Neuronex / Acorda. Collaboration and license.

  • A competitive edge

    TBR 652 is currently being developed by Tobira Therapeutics. A phase IIa proof-of-concept trial evaluated the antiviral activity, safety and pharmacokinetics of TBR 652 in treatment-experienced, CCR5-naïve ... Ampyra (Acorda Therapeutics). Multiple

  • MS symptom drug approved in US

    The drug will be manufactured by Irish pharmaceutical company, Elan, and will be distributed in the US by Acorda Therapeutics. ... Shane Cooke, executive vice president and head of Elan Drug Technologies said: "We wish to congratulate Acorda Therapeutics

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    847. Lineage Therapeutics/Impax Laboratories. Company acquisition. Includes generic and branded products such albendazole and epinephrine. ... 675. Acorda Therapeutics/Civitas Therapeutics. Company acquisition. Includes CVT 301 in P3 for Parkinson's as

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Dr Catherine Strader joins Acorda Therapeutics’ board Dr Catherine Strader joins Acorda Therapeutics’ board

    Dr Catherine Strader joins Acorda Therapeutics’ board. She brings experience from Merck &Co and Synergy Partners R&D Solutions. ... Acorda Therapeutics has expanded its board of directors with the addition of Dr Catherine Strader.

  • Acorda Therapeutics appoints chief medical officer Acorda Therapeutics appoints chief medical officer

    Acorda Therapeutics appoints chief medical officer. Interim CMO Dr Burkhard Blank takes on the post in a permanent capacity. ... New York-based biotech Acorda Therapeutics has appointed Dr Burkhard Blank as its chief medical officer.

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics